POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1

Abstract

Background To detect and investigate the expression of POU domain class 2 transcription factor 2 (POU2F2) in human lung cancer tissues, its role in lung cancer progression, and the potential mechanisms. Methods Immunohistochemical (IHC) assays were conducted to assess the expression of POU2F2 in human lung cancer tissues. Immunoblot assays were performed to assess the expression levels of POU2F2 in human lung cancer tissues and cell lines. CCK-8, colony formation, and transwell-migration/invasion assays were conducted to detect the effects of POU2F2 and AGO1 on the proliferaion and motility of A549 and H1299 cells in vitro. CHIP and luciferase assays were performed for the mechanism study. A tumor xenotransplantation model was used to detect the effects of POU2F2 on tumor growth in vivo. Results We found POU2F2 was highly expressed in human lung cancer tissues and cell lines, and associated with the lung cancer patients’ prognosis and clinical features. POU2F2 promoted the proliferation, and motility of lung cancer cells via targeting AGO1 in vitro. Additionally, POU2F2 promoted tumor growth of lung cancer cells via AGO1 in vivo. Conclusion We found POU2F2 was highly expressed in lung cancer cells and confirmed the involvement of POU2F2 in lung cancer progression, and thought POU2F2 could act as a potential therapeutic target for lung cancer.

Escape From Oncogene-Induced Senescence is Controlled by POU2F2 and Memorized by Chromatin Scars

“…Foremost, we identified POU2F2 as a critical factor that promotes OIS escape in vitro and provided compelling evidence that POU2F2 performs a similar function during CRC development, where its overexpression and increased activity are associated with a proliferative and inflammatory transcriptional program as well as decreased overall survival. Furthermore, this putative function of POU2F2 in CRC is consistent with recent evidence demonstrating its role in the progression of cancers in several tissues, including in stomach, lung, brain, and germinal B-cell lymphomas, where it regulates transcriptional networks that alter metabolic pathways, promotes cell proliferation and metastasis and activates cell differentiation programs [55][56][57]81 . Collectively, these findings highlight POU2F2 as a potential therapeutic target in CRC.…”

“…Consistent with recent evidence implicating POU2F2 in facilitating cancer progression in various tissues, including the brain, stomach, and lung, [55][56][57] , increased POU2F2 mRNA expression in primary CRCs was associated with decreased overall survival (Figure 6A). To understand how POU2F2 contributes to CRC, we performed footprinting analysis on chromatin accessibility datasets of 12 normal human colon tissue (from 5 donors) and 38 human CRCs, which revealed significantly upregulated POU2F2 chromatin binding activity in CRCs relative to normal tissue (Figure 6B).…”

A multi-omics approach for biomarker discovery in neuroblastoma: a network-based framework

“…In glioblastoma, it has been reported to regulate the metabolic shift from oxidative phosphorylation to glycolysis (The Warburg effect fundamental theory 74 ) via PI3K/Akt/mTOR pathway promoting tumor cells proliferation, growth, and survival 75 . It promotes lung cancer's proliferation and mesenchymal characteristics via upregulating AGO1 76 . In NB, POU2F2 is responsible for cell development and proliferation and was reported in previous bioinformatics analyses to be hypermethylated, which drives its downregulation 77,78 .…”

Identification of genetic biomarkers, drug targets and agents for respiratory diseases utilising integrated bioinformatics approaches

“…The YY1 modulates Lung Cancer Progression and other lung diseases 60 . POU2F2 could function as a potential therapeutic target for lung cancer because it was significantly expressed in lung cancer cells 61 .…”